Key facts
- Gensaic’s last known valuation is $17.0M (Jun 2021).
- It has raised $13.5M; the latest was Later Stage VC in Mar 2025.
- Notable investors include Cystic Fibrosis Foundation, Novo Nordisk, Ovid Therapeutics.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Gensaic
- ·The full record, as it builds
Funding rounds
No funding rounds for Gensaic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gensaic
Developer of a machine-guided protein design platform designed to create tissue-selective, intracellular therapies for metabolic and age-related diseases. The company offers a DNA-barcoded protein evolution engine that combines large-scale in vivo screening with predictive protein modeling, enabling patients with muscle-wasting and obesity to benefit from precisely delivered, dual-targeting siRNA therapies.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 10
- Website
- gensaic.com/
- Ownership
- Privately Held (backing)
Gensaic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gensaic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gensaic in its N-PORT filings yet. We sweep new filings monthly.